UPDATE : Friday, June 5, 2020
Abbott markets new stent for treating coronary artery disease
  • By Lee Han-soo
  • Published 2018.11.16 16:45
  • Updated 2018.11.16 17:19
  • comments 0

Abbott Korea said Thursday that it has launched XIENCE Sierra, a stent used for coronary artery disease, in Korea.

The stent is the latest version of the everolimus drug-releasing XIENCE stent lineup. The company has also completed registering for insurance coverage with the Ministry of Health and Welfare.

XIENCE is one of the most used stents in the world and has proved its safety due to low side effects. XIENCE Sierra is an upgraded version over the existing XIENCE stent system, with improved stent design, new catheter system and additional size.

The company expects that the improvements will allow the medical staff to help with complex lesions, such as complex vascular occlusion, that has not been easy to treat.

According to Abbott, about 70 percent of cases requiring stents have complex vascular occlusion symptoms.

The device has an innovative design, including thinner profiles, greater flexibility, and longer dimensions. The company designed the stent for treating complicated and complex patients, such as multiple clogged blood vessels or completely blocked cases.

“XIENCE Sierra was developed to allow medical staff to have a successful surgery in situations where conventional stents could not work,” Abbott Korea’s Vascular Division President Park Dong-taek said. “XIENCE Sierra's upgraded design and improved catheter system allow more accessible lesion access and reperfusion than conventional stents while improving treatment flexibility and accuracy.”

More than 8 million patients have received Abbott’s XIENCE stent system since the company won approval in Europe in 2006 and U.S. in 2008. The lineup has also proved its safety compared with other products as it has over 100 clinical trials and 10 years of user experience since its launch.

The Ministry of Food and Drug Safety approved XIENCE Sierra in August.


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top